Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bioflavonoids, particularly subclasses such as flavonols (e.g., quercetin) and flavan-3-ols, have been investigated for their potential role in supporting or treating diabetic retinopathy. Their purported benefits stem from antioxidant, anti-inflammatory, and vascular-protective properties. Some studies, including small clinical trials and animal research, have shown that certain bioflavonoids (notably a mixture known as "diosmin" and "hesperidin") may help reduce retinal vascular leakage and oxidative stress, both of which are key factors in the progression of diabetic retinopathy. Additionally, bioflavonoids may help stabilize capillary walls and reduce microvascular complications by inhibiting the formation of advanced glycation end products (AGEs) and modulating pathways involved in retinal inflammation.

However, the body of evidence remains limited. Most of the supportive data come from preclinical models or small-scale human studies with methodological limitations. Systematic reviews and meta-analyses have not yet established a robust, consistent benefit in large, well-controlled clinical trials. As such, while there is some scientific rationale and preliminary evidence for the use of bioflavonoids in diabetic retinopathy, the overall strength of the evidence is weak to moderate (rated 2/5). Use of bioflavonoids for diabetic retinopathy should be considered adjunctive and not a replacement for established medical therapies. More rigorous clinical trials are needed to confirm efficacy and safety in this context.

More about Bioflavonoid
More about Diabetic Retinopathy

Other ingredients used for Diabetic Retinopathy

Other health conditions supported by Bioflavonoid

Products containing Bioflavonoid